Concarlo Therapeutics

Concarlo is a preclinical oncology company, focused on becoming the world leader in p27Kip1 cancer biology. We are developing therapeutics to extend the lives of cancer patients, beginning with women with metastatic breast cancer. Approximately 37,000 U.S. women will be diagnosed with metastatic ER/PR+, HER2- breast cancer this year. Despite recent advances, the 5 year survival rate is only 29%. Concarlo is exploiting the discovery that master regulator, p27, controls CDK4/6 and CDK2 activity and resistance, and has developed technologies to recognize and stop this pathway. Drugging CDK2 directly has been difficult and usually results in significant toxicity. Concarlo's approach is more specific, less toxic, and causes tumor regression. Our vision is for a world with better outcomes for high risk cancer patients by drugging this transformative target using our data driven understanding of this mechanism.